🔥 TRENDING Singer‑songwriter Anuv Jain shifts to... Bhopal's AQI jumps 70 points after Diw... Top 5 Pankaj Tripathi Thriller Films t... Congress outpaces BJP by 14 lakh votes... Forgotten Bengali Disco Track Revived... बिहार के नर्सिंग व पैरामेडिकल कॉलेजों...
21 Nov 2026•
ગુજરાતી मराठी ਪੰਜਾਬੀ বাংলা
FDA Delays Verdict on Vision‑Loss Drug, BLTE Shares Plunge to Two‑Year Low
📷 Image: Wikimedia Commons / USDAgov
Business

FDA Delays Verdict on Vision‑Loss Drug, BLTE Shares Plunge to Two‑Year Low

✍️ Asianet Newsable 🗓 21 Nov 2026, 08:22 AM 👁 13
Share: 💬 WhatsApp 📘 Facebook 𝕏 Post

The U.S. Food and Drug Administration has postponed its decision on a new vision‑loss treatment, sending BLTE’s stock tumbling to its lowest level in almost two years.

The U.S. Food and Drug Administration announced a postponement of its pending decision on a novel therapy aimed at treating vision loss. The agency did not specify a new timeline for the review, leaving the outcome uncertain for the drug’s developer.

Following the announcement, shares of BLTE, the company behind the drug, fell sharply on the trading floor, marking the steepest one‑day decline the stock has seen in nearly two years. Investors reacted swiftly, selling off the equity as the regulatory delay introduced heightened risk to the company’s pipeline.

Market analysts noted that the postponement could delay potential revenue streams tied to the drug’s launch, pressuring the firm’s financial outlook. While the FDA’s move does not reflect a negative assessment of the product, the uncertainty has amplified short‑term volatility in BLTE’s market valuation.

The drug, which targets a condition that affects millions worldwide, remains under investigation, and the company has pledged to keep stakeholders informed as the FDA’s review progresses.
📲Get App